• CMS Proposed Updates to Policies and Payment Rates for End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (CMS 1674-P) Issues related to survey and certification of dialysis facilities under sub-regulatory guidance issued by the CMS Centers for Clinical Standards and Quality Issues related to charitable premium assistance for individuals with ESRD CMS-1691-P: End Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End Stage Renal Disease Quality Incentive Program; and various sub-regulatory guidance from the CMS Centers for Clinical Standards and Quality governing dialysis facility accreditation and dialysis services furnished in skilled nursing facilities; and issues related to sub-regulatory guidance affecting dialysis facility accreditation and dialysis care furnished in a skilled nursing facility.

Duration: June 1, 2017 to January 10, 2019

General Issues: Medicare/Medicaid, Health Issues

Spending: about $450,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2017: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS)

Related Foreign Entities: Fresenius Medical Care AG (Bad Homburg, GER); contribution to lobbying: $0; ownership 43%